AAL

Analyst Update: Peabody Energy, Ambarella, aTyr Pharma

Analysts adjusted their ratings and price targets on Peabody Energy Corporation (NYSE:BTU), Ambarella Inc (NASDAQ:AMBA), and aTyr Pharma Inc (NASDAQ:LIFE)

Jun 1, 2015 at 1:31 PM
facebook X logo linkedin


Analysts are weighing in on coal concern Peabody Energy Corporation (NYSE:BTU), semiconductor specialist Ambarella Inc (NASDAQ:AMBA), and drugmaker aTyr Pharma Inc (NASDAQ:LIFE). Here's a quick roundup of today's brokerage notes on BTU, AMBA, and LIFE.

  • BTU has earned a dreary spot on the Big Board, after Goldman Sachs initiated coverage on the stock with a "sell" rating and a $2 price target, citing concerns over domestic thermal coal demand. At last check, the security was down 6.2% at $3.16, and fresh off a record low of $3.15. Today's negative price action just echoes the withstanding trajectory of a security that's surrendered 80% of its value year-over-year. Peabody Energy Corporation could encounter a fresh wave of selling pressure, too, should any analysts follow in Goldman Sachs' footsteps. Currently, seven out of 17 brokerage firms maintain a "buy" or better rating on the equity, while the average 12-month price target of $7.10 stands at a 125% premium to BTU's present perch.

  • Ahead of AMBA's turn in the earnings confessional tomorrow night, Deutsche Bank raised its price target on the stock to $80 from $64. The bullish brokerage note has sent the shares soaring to yet another record high; this time, with AMBA topping out at $93.86. Longer term, the stock has added 85% in 2015, and was last seen lingering near $93.73. In the options pits, speculators have shown an increasing preference for puts over calls among options set to expire in three months or less. Specifically, Ambarella Inc's Schaeffer's put/call open interest ratio (SOIR) has jumped to 1.10 from its May 18 reading of 0.94, and now ranks in the 66th percentile of its annual range.

  • Wall Street newcomer LIFE received a bevy of bullish brokerage notes, and has moved 2.1% higher to $23.36 as a result. Both BMO and William Blair, for example, initiated coverage with an "outperform" rating and a $42 price target. Elsewhere, J.P. Morgan Securities started the stock with an "overweight" recommendation and a $44 target price, while Citigroup began coverage with a "buy" suggestion and a $32 price target. Since going public on May 7, aTyr Pharma Inc has tacked on more than 75%, and topped out at a post-IPO peak of $27.82 on May 21.
 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.